Cargando…

Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines

BACKGROUND: Studies in taxane and/or anthracycline refractory metastatic breast cancer (mBC) patients have shown approximately 30 % response rates to irinotecan. Hence, a significant number of patients will experience irinotecan-induced side effects without obtaining any benefit. The aim of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jandu, Haatisha, Aluzaite, Kristina, Fogh, Louise, Thrane, Sebastian Wingaard, Noer, Julie B., Proszek, Joanna, Do, Khoa Nguyen, Hansen, Stine Ninel, Damsgaard, Britt, Nielsen, Signe Lykke, Stougaard, Magnus, Knudsen, Birgitta R., Moreira, José, Hamerlik, Petra, Gajjar, Madhavsai, Smid, Marcel, Martens, John, Foekens, John, Pommier, Yves, Brünner, Nils, Schrohl, Anne-Sofie, Stenvang, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722663/ https://www.ncbi.nlm.nih.gov/pubmed/26801902 http://dx.doi.org/10.1186/s12885-016-2071-1

Ejemplares similares

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies
por: Schrohl, Anne-Sofie, et al.
Publicado: (2011)

Recent advances in lineage differentiation from stem cells: hurdles and opportunities?
por: Terryn, Joke, et al.
Publicado: (2018)

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2017)

The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells
por: Hansen, Stine Ninel, et al.
Publicado: (2016)

Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study
por: Schrohl, Anne-Sofie, et al.
Publicado: (2009)

A Bacteriophage-Acquired O-Antigen Polymerase (Wzy(β)) from P. aeruginosa Serotype O16 Performs a Varied Mechanism Compared to Its Cognate Wzy(α)
por: Taylor, Véronique L., et al.
Publicado: (2016)

Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study
por: Thorsen, Stine B, et al.
Publicado: (2013)

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2017)

The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer
por: Lin, Xue, et al.
Publicado: (2015)

Topoisomerase I as a Biomarker: Detection of Activity at the Single Molecule Level
por: Proszek, Joanna, et al.
Publicado: (2014)

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
por: Kümler, Iben, et al.
Publicado: (2015)

BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity
por: Rasmussen, Rikke D., et al.
Publicado: (2016)

Author Correction: BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity
por: Rasmussen, Rikke D., et al.
Publicado: (2018)

VEGF-C as a putative therapeutic target in cancer
por: Michaelsen, Signe R., et al.
Publicado: (2019)

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
por: Kümler, Iben, et al.
Publicado: (2019)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
por: Yue, Bei, et al.
Publicado: (2021)

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
por: Mahdy, Marwa S., et al.
Publicado: (2023)

The Widespread Multidrug-Resistant Serotype O12 Pseudomonas aeruginosa Clone Emerged through Concomitant Horizontal Transfer of Serotype Antigen and Antibiotic Resistance Gene Clusters
por: Thrane, Sandra Wingaard, et al.
Publicado: (2015)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2020)

Effects of methimazole on the elimination of irinotecan
por: van der Bol, Jessica M., et al.
Publicado: (2010)

Masked Speech Recognition by Normal-Hearing 6–13-Year-Olds in Conditions With and Without Interaural Difference Cues
por: Neher, Tobias, et al.
Publicado: (2022)

Orally active bivalent V(H)H construct prevents proliferation of F4(+) enterotoxigenic Escherichia coli in weaned piglets
por: Fiil, Berthe Katrine, et al.
Publicado: (2022)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
por: Yang, Liuting, et al.
Publicado: (2018)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

DNA-Based Sensor for Real-Time Measurement of the Enzymatic Activity of Human Topoisomerase I
por: Marcussen, Lærke Bay, et al.
Publicado: (2013)

Irinotecan toxicity: genes or intestinal microflora?
por: Brandi, G, et al.
Publicado: (2009)

Herbal Medicines for Irinotecan-Induced Diarrhea
por: Tang, Liu, et al.
Publicado: (2019)

Irinotecan-Induced Steatohepatitis: Current Insights
por: Han, Jun, et al.
Publicado: (2021)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
por: Quackenbush, Kevin S., et al.
Publicado: (2016)

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

Formulation and Evaluation of Irinotecan Suppository for Rectal Administration
por: Feng, Haiyang, et al.
Publicado: (2014)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

Irinotecan-Induced Serpentine Supravenous Hyper-Pigmentation
por: Gaurav, Vishal, et al.
Publicado: (2022)

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities
por: Waterhouse, Dawn N., et al.
Publicado: (2014)

Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis()()
por: Erdem, Zeynep N., et al.
Publicado: (2017)

Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
por: Scarabel, Lucia, et al.
Publicado: (2020)

The Use of Longitudinal (18)F-FET MicroPET Imaging to Evaluate Response to Irinotecan in Orthotopic Human Glioblastoma Multiforme Xenografts
por: Nedergaard, Mette K., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vc6argnph5dk8m7nse6jk9pssb